Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Open a printable version of this pageEmail the URL of this page to a friend
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Subscribe To Our Newsletter & Stay Updated
